Clinical Trials Logo

Filter by:
NCT ID: NCT04769921 Active, not recruiting - Edentulous Jaw Clinical Trials

Full Arch Rehabilitations Through the Contemporary All-on-4 Concept

AO4ContProt
Start date: February 19, 2019
Phase:
Study type: Observational

It is necessary to generate more evidence on the outcome of contemporary protocols for full-arch rehabilitations supported by implants in immediate function in areas with limited quantity and density bone. This research project aims to investigate the outcome of fixed prosthetic restorations supported by implants in immediate function for full-arch rehabilitation through the All-on-4 concept contemporary protocol, specifically: implant survival and success, prosthetic survival, marginal bone level and marginal bone level changes, soft tissue health parameters (Plaque index, Bleeding index, Pocket depth), incidence of biological and mechanical complications. A prospective cohort study design will be used in the investigation. The sample of this study is estimated to consist in 43 patients rehabilitated with full-arch fixed prosthetic rehabilitations supported by implants in immediate function (All-on-4 concept) with 144 dental implants. The cohort will be evaluated between baseline and 3 years of follow-up.

NCT ID: NCT04768231 Not yet recruiting - Tuberculosis Clinical Trials

Rifampicin at High Dose for Difficult-to-Treat Tuberculosis

RIAlta
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety of rifampicin given at a dose three times as the standard one, in persons with tuberculosis that belong to groups that have not been widely included in previous trials.

NCT ID: NCT04768218 Completed - Gastric Cancer Clinical Trials

BLI for the Diagnosis of Precancerous Conditions

Start date: March 1, 2021
Phase:
Study type: Observational

Introduction: Traditionally, White Light Endoscopy (WLE), enhanced by biopsies following the updated Sydney system guidelines, has been the benchmark for diagnosing and classifying gastric preneoplastic conditions. Nevertheless, the pronounced interobserver variability and the often weak correlation between endoscopic observations and histopathological results have driven the increasing adoption of virtual chromoendoscopy (VCE). VCE technologies have demonstrated greater effectiveness in identifying these conditions compared to WLE, with Narrow Band Imaging (NBI) being particularly notable. Significantly, NBI has played a key role in validating the Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) system. However, data on the effectiveness of other VCE technologies in this domain is relatively sparse in Europe, specifically with Blue Light Imaging (BLI), despite the promising diagnostic performance demonstrated with this technology. Primary aim: to assess the diagnostic accuracy of BLI and to externally validate the applicability of EGGIM classification for staging GIM. Material and methods: a multicentric cohort study will be performed involving centres from two European countries (Portugal, Italy). Consecutive patients performing upper gastrointestinal endoscopy will be evaluated by WLE and BLI. Random biopsies or targeted plus random biopsies will be performed in order to determine de accuracy of BLI system to detect and stage GIM. Expected results: We anticipate that BLI would enable us to assess the extension of GIM without the need for biopsies. If observed, this would overall improve the upper GI endoscopy accuracy.

NCT ID: NCT04764656 Active, not recruiting - Clinical trials for Neovascular Age-related Macular Degeneration (nAMD)

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

BLUESKY-PT
Start date: May 10, 2021
Phase:
Study type: Observational

This study is a prospective, observational, non-interventional, multicenter, open-label, single arm study in patients being treated for nAMD with brolucizumab in Portugal.

NCT ID: NCT04764448 Active, not recruiting - Clinical trials for Alpha 1-Antitrypsin Deficiency

A Study of Belcesiran in Patients With AATLD

ESTRELLA
Start date: February 12, 2021
Phase: Phase 2
Study type: Interventional

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult patients with PiZZ AATD-associated liver disease (AATLD). The study will be conducted in 3 separate cohorts. A total of up to 16 participants may be enrolled in Cohort 1 and 2. A total number of 30 subjects will be enrolled in cohort 3. The 3 cohorts are differentiated by the duration of the treatment period, the number of doses administered, and the timing of the second liver biopsy.

NCT ID: NCT04764188 Active, not recruiting - NSCLC Clinical Trials

An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

ReAlec
Start date: May 10, 2021
Phase:
Study type: Observational

This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

NCT ID: NCT04763408 Active, not recruiting - Clinical trials for Carcinoma, Hepatocellular

A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

STELLAR
Start date: April 9, 2021
Phase:
Study type: Observational

The primary purpose of this study is to further characterise the hepatotoxicity in participants with advanced or unresectable hepatocellular carcinoma (HCC) treated with lenvatinib, and to further characterise the overall safety profile (serious adverse events [SAEs], grade 3 to 5 adverse events [AEs], dose modifications and discontinuations due to AEs) in participants with advanced or unresectable HCC treated with lenvatinib.

NCT ID: NCT04762992 Enrolling by invitation - Pre-Eclampsia Clinical Trials

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

HepaGrowth
Start date: July 6, 2023
Phase: Phase 3
Study type: Interventional

Early fetal growth restriction (FGR) is associated with considerable fetal and neonatal morbimortality (Miller et al. 2008, Nardozza et al. 2017). Placental thrombosis, infarcts and hypercoagulability are frequently seen in these pregnancies, suggesting a role for the activation of the coagulation cascade in the genesis of FGR. Patients will be randomized for low-molecular weight heparin or standard of care, and the outcomes of both arms (gestational age at delivery, gestational and fetal morbidity) will be compared.

NCT ID: NCT04762420 Completed - Anesthesia Clinical Trials

Sugammadex Dosing: Anaesthesiologist Clinical Perception Versus Quantitative Monitoring

Start date: February 1, 2019
Phase:
Study type: Observational

Many clinicians continue to rely on subjective evaluation in making decisions about the adequacy of neuromuscular function before tracheal extubation rather than using quantitative monitoring. The aim was to compare the sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience versus the dose determined by quantitative monitoring (QSD) to determine if the subjective dose was appropriate.

NCT ID: NCT04756635 Recruiting - Men Clinical Trials

Effects of Short- Term Intermittent Fasting Aerobic and Anaerobic Capacity

Performance
Start date: May 22, 2018
Phase: N/A
Study type: Interventional

The therapeutic use of caloric restriction and intermittent fasting (IF) protocols improves life span and health related quality of life. The effects of fasting protocols on athletic performance and training adaptations have been primarily studied in athletes undergoing the Ramadan IF protocol or in athletes willing to decrease body fat, while maintaining or increasing lean body mass. Data from these studies are somewhat conflicting and unclear. Moreover, the effects of IF on muscular strength, as well as in aerobic and anaerobic capacity remain largely unknown. Anecdotal evidence from experienced participants in strength, power and endurance training or sports, indicates an increased ability to acutely display higher levels of work capacity in the fasted vs. fed state. The goal of this project is to determine the effects of 4 wks of IF on neuromuscular performance, aerobic and anaerobic capacity of well-trained young adults.